Zecotek Photonics clarifies news release on TGFL provided to the National Institute of Health

Zecotek Photonics Inc. (TSX VENTURE:ZMS)(FRANKFURT:W1I), a developer of leading-edge photonics technologies for medical, industrial and scientific markets, today announced an update and clarification to the news release of December 15, 2009 titled "National Cancer Institute Selects Zecotek's Tunable Green Fiber Laser for Applications in Flow Cytometry."

Zecotek wishes to clarify that the new Tunable Green Fiber Laser (TGFL) provided to the National Institute of Health (USA) was assembled by Zecotek as a pre-production prototype sample. The warranty of the said pre-production laser is provided at this trial stage solely by Zecotek and not Fujikura. Results from NIH testing, together with feedback from major customers will be used as inputs to guide the final design features prior to the transfer for commercial production.

As such, the statements in the December 15th news release were released unilaterally by Zecotek without Fujikura's contribution or revision.

Fujikura will manufacture the commercial production version of the TGFL in accordance with terms and conditions of the agreement and documented arrangements on distribution and labeling between Zecotek and Fujikura.

The present clarification is mutually agreed on by Zecotek and Fujikura.


Zecotek Photonics Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.